BioCentury
VerifiedOnline/Digital
Since 1993, BioCentury, Inc. has been internationally recognized as the leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures.
BioCentury employs a fully integrated multimedia platform — including publications, video, online data solutions and conferences — to provide its audience with authoritative and up-to-date intelligence about corporate strategy, partnering, emerging technology, clinical data, public policy and the financial markets.
BioCentury's Editorial and Research staff comprise industry-recognized business and science editors and writers. The Company's management team includes executives with backgrounds in international business, publishing, finance, and the biotech and pharmaceutical industries.
BioCentury is headquartered in Redwood City, Calif., with offices in Washington, D.C.; Chicago; and London. Source
Actions
Media Outlet details
| Scope | International, Trade/B2B |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesMaking center directors permanent latest signal of stability for FDA
ARTICLE | Politics, Policy & Law ‘Acting’ no more: HHS signals intent to maintain current direction with appointments of Davis, Mikhail By Steve Usdin, Washington Editor In a move that solidifies FDA’s operational leadership, the Trump administration has made Michael Davis CDER Director and Karim Mikhail CBER Director. They had been serving as acting center directors since May. Jared Seehafer has been named to a new position, Deputy Commissioner for Technology and Artificial Intelligence.
The factors that could have contributed to Novartis’ Lp(a) miss
ARTICLE | Product Development Antisense therapy pelacarsen from Novartis failed to improve cardiovascular outcomes in Phase III By Lauren Martz, Executive Director, Biopharma Intelligence The Phase III miss by Novartis’ pelacarsen is a blow to the pharma’s first-in-class Lp(a) aspirations. Depending on what the full data show — and whether subsequent programs succeed — it could also have implications for antisense oligos, other RNA modalities, and cardiovascular R&D more broadly.
Novartis’ Phase III misses, pharma deals analysis, MFN carve-outs — a BioCentury podcast
PODCAST | Product Development Plus: A tribute to Peter Barton Hutt, who helped shape drug law for decades By BioCentury Staff • Novartis and Lp(a) fallout — Pelacarsen's Phase III failure has shaken confidence in a genetically supported cardiovascular target and ignited a debate over whether issues with the target, modality or treatment setting contributed to the lack of efficacy.
Novartis’ Phase III misses compound Novo’s cardiovascular setback
ARTICLE | Product Development BioCentury’s Clinical Report, Sept. 4-8 By Tierney Baum, Biopharma Analyst Novartis reported two Phase III misses over the past five days, while Novo halted two late-stage heart failure trials following the failure of an earlier cardiovascular outcomes study. In both companies’ cardiovascular programs, successful target engagement failed to translate into clinical benefit.
Targeting persistent necroptotic-to-apoptotic epithelial signaling in IBD
ARTICLE | Distillery Therapeutics Targeting the necroptotic-to-apoptotic epithelial death axis could promote deeper remission in IBD by blocking a pathogenic program that persists despite advanced therapy. Patient biopsies and human intestinal models showed that early inflammation drives an M1 macrophage-like epithelial state with RIPK1-independent necroptotic signaling, followed by NOS2-mediated mitochondrial apoptosis of absorptive cells and PUMA-mediated intestinal stem cell death.
Blocking platelet serotonin signaling to reduce age-related COVID-19 lung injury
Need just this one Article text only: no BCIQ data, AI Connectors, deal comparables, or coverage as the story develops.
“Zollo body” translation compartment required for mammalian oocyte growth
ARTICLE | Distillery Therapeutics “Zollo body” translation compartment required for mammalian oocyte growth BC Staff September 9, 2026 1:03 AM GMT The transient “Zollo body” identifies a translation-associated ribonucleoprotein compartment required for mammalian oocyte and follicle growth. Researchers combined imaging, mass spectrometry, electro...
“SpotMAX” for automated multidimensional fluorescence spot detection and quantification
ARTICLE | Distillery Therapeutics “SpotMAX” for automated multidimensional fluorescence spot detection and quantification BC Staff September 9, 2026 1:02 AM GMT “SpotMAX” enables automated detection, segmentation, and quantification of fluorescent spots across multidimensional microscopy datasets. The generalist framework is designed for 2D through 5D imaging... Need just this one Article text only: no BCIQ data, AI Connectors, deal comparables, or coverage as the story develops.
“Spatial Hi-C-RNA” for joint spatial profiling of 3D genome organization and transcription
Cookie Policy When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies.
MEIS2 restoration of PV interneuron plasticity to improve cognition in neurodevelopmental disorders
Cookie Policy When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies.